Accrol Group Holdings plc H1 21 Half Year Results Presentation January 2021

0 0 0

H1 Performance

Highlights

- All operations operated safely and successfully throughout the pandemic & ongoing
- Significant investment in COVID protection for all
- Continued Margin Improvement
- Strong cash generation with net debt reducing faster than anticipated

Delivering on our Shareholder Promises

- Intention to restore dividend payments for FY21 minimum payment 0.5p per share
- Net debt expected to be below market consensus for FY21 and FY22

Growing Confidence on the Future

- Integration of LTC has begun better than expected
- Margins continuing to strengthen into H2
- Fully on track to deliver FY21 at least in line with market expectations

Proven Management Team

An experienced team with a track record of delivering industry leading growth and returns





Dan Wright Executive Chairman Date appointed - 4 February 2018

Key strengths

- · 25 years experience in PE and over 50 transactions, UK wide reputation of delivering exceptional returns
- Dynamic leader bringing great teams together



Gareth Jenkins Chief Executive Officer Date appointed - 11 September 2017

Key strengths

 Extensive strategy, commercial, M&A and operational experience, UK and in Europe Track record of delivering industry leading returns in manufacturing environments



Richard Newman Chief Financial Officer Date appointed - 1 February 2021

Key strengths

- · Extensive strategy, commercial, M&A and Senior Financial leadership experience in the UK and mainland Europe
- PWC, Mondelez, Stagecoach & DS Smith senior financial positions



Euan Hamilton Independent Non Exec Director Date appointed - 27 August 2018

Key strengths

- Restructuring and business turnarounds
- Leverage finance and private equity
- Investment banking worldwide



Simon Allport Independent Non Exec Director Date appointed - 10 October 2018

Key strengths

- Extensive commercial & M&A experience
- · Broad strategic experience throughout many industries



Graham Cox Managing Director Tissue Division

Key Strengths

- · 20 years experience at DS Smith, running manufacturing business and delivering exceptional returns
- · US operations' MD 1,200 employees and £450m revenue - significant multisite turnaround



Mark Dewhurst Chief Operating Officer

Key Strengths

- Extensive Operational experience across sectors and geographies
- · Significant experience in M&A and business integration across multiple geographies



Kathryn Robinson HR Director

Kev Strenaths

 Significant experience in people restructure programmes across a wide range of manufacturing environments



Lyndsey Marsh Head of Finance

Key Strengths

· Supports operational leaders and teams to make good commercial decisions

Grow

Simplify



Financial Results – H1 2021

	H1 21	H120	H119	Change	Change
	£m	£m	£m	£m	%
Underlying Results				·	
Core revenue	62.3	64.5	53.9	(2.2)	(3.5%)
Adjusted gross profit ¹	15.4	13.0	9.9	2.4	18.5%
Adjusted gross margin	24.7%	20.0%	17.2%	470bp	23.5%
Adjusted EBITDA ²	5.4	3.2	(1.1)	2.2	68.8%
			F7 6	(2.0)	(1 20/)
Reported Results Total revenue	62.3				
		65.1	57.6	(2.8)	· · · · · ·
Gross profit	14.8	12.8	6.9	2.0	15.6%
Gross profit Administration & Distribution expenses	14.8 14.5	12.8 15.0	6.9 15.3	2.0 0.5	15.6%
Gross profit Administration & Distribution expenses Operating profit	14.8	12.8	6.9	2.0	(4.3%) 15.6% (3.3%)
Gross profit Administration & Distribution expenses Operating profit	14.8 14.5	12.8 15.0	6.9 15.3	2.0 0.5	15.6% (3.3%)
Gross profit Administration & Distribution expenses	14.8 14.5 0.3	12.8 15.0 (2.1)	6.9 15.3 (8.4)	2.0 0.5 2.4	15.6%
Gross profit Administration & Distribution expenses Operating profit Gross margin	14.8 14.5 0.3 23.8%	12.8 15.0 (2.1) 19.7%	6.9 15.3 (8.4) 12.0%	2.0 0.5 2.4 410bp	15.6% (3.3%)

Continued Improvement in Performance

Gross Margins up 24% Net debt down 37% Costs down 3.3% Gross profit up 18.5%

Revenue down 3.5% but share up 14% When adjusted for retailer margin improvement

¹ Adjusted gross profit excludes turnaround and operational costs reported in cost of sales

² Adjusted EBITDA is defined as profit before finance costs, tax, depreciation, amortisation, exceptional costs, share based payments, & IFRS 16 changes is a non-GAAP metric used by management and is not an IFRS disclosure

OPERATIONAL IMPROVEMENT is relentless

"Simplification in all we do"

THE <mark>RIGHT</mark> PEOPLE

STRONG FOUNDATIONS

53% reduction in people

100% new leadership Head count from 689 to 325 TARGET <300 (Accrol)

£0.5m cost base reduction

Administration and distribution costs £14.5m H1 21 £15.0m H1 20

+470bp increase in adjusted Gross Margin

from 20.0% to 24.7%

77% employee engagement

76% management support **72%** believe in team work culture

19% Reduction in dist

Reduction in distribution costs

6.8% of sales in H1 21 8.4% of sales in H1 20

increase in EBITDA

from £3.2m to £5.4m

+69%

n H1 21 n H1 20

37% reduction in accidents

26 Accidents H1 21 41 Accidents H1 20

£5.5m *free cash flow improvement*

16 day improvement in creditor days **14 day** improvement in debtor days

+£6.7m reduction in Net Debt (per IFRS 16)

from £24.8m to £18.1m

GENERATE SHAREHOLDER RETURNS



Our vision is to deliver the best possible value to the UK consumer on everyday essential tissue products

Accrol is a leading UK independent tissue converter, producing private label toilet roll, kitchen roll and facial tissue products for many of the UK's major grocery retailers



Accrol delivered 14.5% growth in FY20, compared with 6.9% in the total market – we continue to match capacity to growth

"We are shaking up traditional brands by delivering the quality the consumer wants for the price they want to pay"

A SIMPLE BUSINESS Building back the gross margin

"Three key areas of focus drive our gross margin: materials, people and overhead cost"



The route back to 10%+ business **FY18 FY19 FY20** H121 £140m 100% Revenue £62.3m - Revenue £119m £135m 70% Materials 65% Materials 71% 66% 67% - People People 15% 10% 11% 11% 11% - Overheads **Overheads** 20% 17% 14% 15% 16% 8% Adjusted EBITDA Adjusted EBITDA (5%) 1% 7% 10%

*Like for like comparison post IFRS impact


7



Financial results

	H121	H120	FY20	FY 19	FY 18	Target
Revenue Core revenue	£62.3m £62.3m	£65.1m £64.5m	£134.8m £133.6m	£119.1m <i>£116.3m</i>	£139.7m £115.2m	
Adjusted EBITDA (*before IFRS positive impact)	£5.4m	£3.2m	*£8.3m	* £1.0 m	*(£5.8m)	
Net debt	£18.1m	£24.8m	£17.9m	£27.1m	£33.8m	
EBITDA % Sales	8.7%	4.9%	6.2%	0.9%	-4.2%	>10%
Net debt/adjusted EBITDA			2.2x	27.1x	-5.8x	<2x

Credit facility



18% improvement in headroom

Headroom

RCFID LineLease

What they were	What they are	What next
Debtors – 53 days	H121 – 32 days	Credit insurance returning
Creditors – 46 days	H121 – 68 days	Continued improvement
Improve supplier terms	Long term agreement and more	90 day terms for all
Exert cost pressure on suppliers	suppliers Supplier partnerships	Buy or make review

LTC Integration Update

10

AT THE


12

00



1. Integration Process

Structured methodology with formal governance and project management tools



10

Simplify

Strengthen

Grow



2. Value Creation Process

Functional Teams working on identified opportunities to define and deliver value creation projects

Date: 08-Jan-21

ŝ

q


11. Reverse


synergies

Total



High-level status – week ending 18th of December





Shift Pattern / Operational capacity

Customer payment terms harmonisation

Volume, Leverage, Spec Rat, Paper

Volume Leverage, Spec Rat, Packaging

Supplier payment terms harmonisation/improvement

Costs

Working capital

Kantar data

Energy

Security

Security & BAU Stability

Waste Reduction

Consumables

Deferred VAT

Consignment stock

Supplier Analysis

Sales Supply Chain

Operations:

Procurement & Fibre optimisation

Legal, consultancy

Financing charges

Auditing/tax prep

Waste sales/waste costs


OFF KPIs

Insurance

Reduction in raw materials

Price / Cost comparisons

OEE



Grow

Simplify

Strengthen


ACCROL

Our Strategy

Adding value to consumers well being everyday

"Ruthless approach to non-core and its divestment - good products grow in good markets"


Our Ambition - Accrol Group 2020 & Beyond



TRANSFORMATIONAL DELIVERY....WORLD CLASS TEAM WHAT NEXT.....

Market growth as PL displaces Brands driven by product development and positioning outstrip the market **Operational Transformation** a proven track record to execute across multiple sites and geographies Capital discipline controlling leverage whilst growing sales and investing in efficiencies World class team that delivered again and again Strong Financial Outcomes revenue per head, added value per £ total labour, EBITDA, PBT all transformed Shareholder Returns the primary focus





1

18.

-

00

Ale

STATE LA

Shareholder Information (3%+ holders)



Shareholder	Number of shares held	% of issued share capital
Schroder Investment Mgt	36,031,533	11.57
NorthEdge Capital	27,487,377	8.83
Premier Miton Investors	27,268,076	8.76
Canaccord Genuity Wealth Mgt	18,150,646	5.83
Ruffer	15,889,603	5.10
Tellworth Investments	14,275,334	4.58
Killik Asset Mgt	12,490,545	4.01
BlackRock Investment Mgt	12,479,550	4.01
Jupiter Asset Mgt	11,901,382	3.82
Lombard Odier Asset Mgt	10,260,076	3.30
AXA Investment Mgrs	10,079,693	3.24
Daniel Wright	9,972,726	3.20
Total issued share capital (Ordinary shares of £0.001 each)	311,354,632	

As of 18 December 2020 Accrol Group Holdings plc had been made aware of the above shareholdings in the ordinary share capital of Accrol Group Holdings plc

Simplify

Strengthen

Grow

Acquisition Highlights – announced at the time of the deal

Building on our success in the UK



Acquisition of LTC for £35.0 million + up to £6.8 million of deferred consideration

- Well invested, family-owned tissue converter supplying private label & branded toilet roll and kitchen towel to UK retailers
- Four high quality, modern tissue conversion lines, under 6 years old, and strong day-to-day operational leadership team

Highly compelling strategic and financial returns

Commercial opportunity

- Exceptional scale opportunities, enhancing Accrol's customer offer in the toilet roll and kitchen towel sector
- New and complementary customers with limited overlap of Accrol's existing customer base
- Adds significant capacity to existing business, which is already growing faster than the market

Costs

- Clear opportunity to optimise LTC's high quality tissue assets and postpone £5.0m of planned capex for Accrol in FY21
- Logistics efficiencies 48% of Accrol's current volumes delivered south of Leicester
- Minimum of £1.0m costs synergies identified for delivery in first full year of ownership to April 2022

Strategy

- Minimum of 10% EPS accretion expected in the first full year of ownership to April 2022
- Execution of Accrol's "Brand Killers" strategy and demonstration of Group's ambition

Acquisition financing

• c.£38.5m Placing and c.£4.0m Open Offer to cover initial consideration, transaction fees and strengthen the balance sheet



Strengthen

Grow

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested

This presentation is for information purposes only and no reliance may be placed upon it. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this presentation.

This presentation does not constitute or form part of any offer or invitation for sale or subscription of, or any solicitation of any offer to buy or subscribe for, any securities of Accrol Group Holdings plc. The making of this presentation does not constitute a recommendation regarding any such securities.

This presentation contains certain forward-looking statements. Any statement in this presentation that is not a statement of historical fact including, without limitation, those regarding Accrol Group Holding plc's future business, financial condition, financial performance, operations, prospects or developments is a forward-looking statement. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipates", "believes", "envisages", "estimates", "expects", "intends", "hopes", "may", "plans", "targets", "will", "would", "could" or "should" or, in each case, the negative of those, variations or comparable expressions. By their nature, forward-looking statements involve risk and uncertainty as they relate to events which occur in the future. No representation or warranty is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Actual performance or results may differ materially from any future results, performance or achievement expressed or implied by these forward-looking statements. Factors which may give rise to such differences include (but are not limited to) changing business conditions, introduction of competing products by other companies, and changing economic, legal or regulatory conditions. New factors could emerge that could cause Accrol Group Holding plc's business not to develop as it expects. These and other factors could adversely affect the outcome and financial effects of the events specified in this presentation. The forward-looking statements are made by the Directors of Accrol Group Holding plc does not intend to update any forward-looking statements contained in this presentation. Each forward-looking statement speaks only as at 1 September 2019 and Accrol Group Holding plc and its advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward-looking statements in this presentation. No statement in the presentation is int

